论文部分内容阅读
目的:探讨唑来膦酸注射液治疗骨质疏松症出现急性期不良反应(APR)情况及可能的影响因素。方法:调查2013—2014年我院使用唑来膦酸注射液(密固达)的住院患者共186例,应用SPSS 17.0软件进行统计分析。结果:186例次患者中38例出现APR,总发生率为20.43%。主要表现为发热、寒战、乏力、肌肉酸痛、头痛和胃肠不适等症状。Logistic回归分析显示,体重指数(BMI)和降钙素制剂与APR呈负相关(P<0.05)。结论:唑来膦酸注射液APR发生率较高,用药时需注意观察,及时对症处理,保证患者用药安全。APR相关影响因素还有待进一步的深入研究证实。
Objective: To investigate the acute phase adverse reactions (APR) and possible influencing factors of zoledronic acid injection in the treatment of osteoporosis. Methods: A total of 186 inpatients with zoledronic acid injections in our hospital from 2013 to 2014 were analyzed. The data were analyzed by SPSS 17.0 software. Results: Of the 186 sub-patients, 38 showed APR with a total incidence of 20.43%. Mainly fever, chills, fatigue, muscle soreness, headache and gastrointestinal discomfort and other symptoms. Logistic regression analysis showed that body mass index (BMI) and calcitonin preparations were negatively correlated with APR (P <0.05). Conclusion: The incidence of APR in zoledronic acid injection is high, which should be observed and treated symptomatically in time to ensure the safety of patients. APR related factors need further study confirmed.